Form 4: FRACTYL HEALTH, INC.: General Counsel Toomey Reports Stock Option Grants
SEC Form 4 Filing
Sarah Toomey, General Counsel of FRACTYL HEALTH, INC., reports the acquisition of stock options, including those related to performance criteria met after the company's IPO.
Summary
- Sarah Toomey, General Counsel of FRACTYL HEALTH, INC. (GUTS), filed a Form 4 on March 3, 2025, reporting changes in beneficial ownership.
- On February 27, 2025, Toomey acquired stock options for 166,200 shares at an exercise price of $1.46, vesting in equal installments over four years.
- Additionally, Toomey acquired options for 79,380 shares at an exercise price of $15, related to performance criteria from the company's IPO.
- The performance criteria for the 79,380 shares were partially met, with 25% vesting on December 31, 2024, and the remaining 75% vesting over the next three years.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The partial vesting of IPO-related options suggests progress towards company goals.
Positives
- The granting of stock options to the General Counsel aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the General Counsel.
Future Outlook
The remaining 75% of the 79,380 shares related to the IPO performance criteria will vest in substantially equal installments on the first three anniversaries thereof.
Industry Context
Stock option grants are a common practice in the healthcare industry to incentivize and retain key personnel, aligning their interests with the company's long-term success.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech and healthcare industries.
- Companies like Moderna and BioNTech also utilize stock options extensively to incentivize their leadership teams.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage.
Stakeholder Impact
- Shareholders may view the stock option grants positively as they incentivize management to improve company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/01/2024 | Reporting Person was granted an option to purchase 132,300 shares of common stock to vest in the form of shares of the Issuer's common stock in four substantially equal installments on December 31, 2024 and each of the first three anniversaries thereof, subject to the satisfaction of certain performance criteria, in connection with the Issuer's initial public offering. |
| 12/31/2024 | 25% of the 79,380 shares related to the IPO performance criteria vested. |
| 02/27/2025 | Date of stock option grants and determination of partial satisfaction of performance criteria. |
| 03/03/2025 | Date of Form 4 filing. |
| 02/26/2035 | Expiration date for the stock options with an exercise price of $1.46. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.